Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Background: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. Aims: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can improve cognitive flexibility performance and functional brain activity in patients with schizophrenia. Methods: This was a within-subject, randomised, double-blind, placebo-controlled, three-period crossover study using a version of the Intradimensional/Extradimensional (ID/ED) task, optimised for functional magnetic resonance imaging (fMRI), in 10 patients with schizophrenia who were scanned after receiving placebo, 100 µg or 250 µg roflumilast for 8 consecutive days. Data from an additional fMRI ID/ED study of 18 healthy participants on placebo was included to contextualise the schizophrenia-related performance and activations. The fMRI analyses included a priori driven region of interest (ROI) analysis of the dorsal frontoparietal attention network. Results: Patients on placebo demonstrated broad deficits in task performance compared to the healthy comparison group, accompanied by preserved network activity for solution search, but reduced activity in left ventrolateral prefrontal cortex (VLPFC) and posterior parietal cortex for attentional set-shifting and reduced activity in left dorsolateral prefrontal cortex (DLPFC) for reversal learning. These ROI deficits were ameliorated by 250 µg roflumilast, whereas during solution search 100 µg roflumilast reduced activity in the left orbitofrontal cortex, right DLPFC and bilateral PPC, which was associated with an improvement in formation of attentional sets. Conclusions: The results suggest roflumilast has dose-dependent cognitive enhancing effects on the ID/ED task in patients with schizophrenia, and provides sufficient support for larger studies to test roflumilast’s role in improving cognitive flexibility deficits in this clinical population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obsessive-compulsive disorder patients and SCZ patients may exhibit abnormal neural activities in the frontostriatal (eg, cingulate cortex, dorsolateral prefrontal cortex) and frontoparietal (eg, parietal cortex) networks while performing tasks related to inhibition 26 ,29-31 and shifting, 14 ,32-35 suggesting disrupted inhibition-related and shifting-related circuitries as shared deficits across”
From Cognitive Inflexibility Shares Across Schizophrenia and Obsessive-Compulsive Disorder: A Task-Based Functional MRI Study (2025) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A fast diffeomorphic image registration algorithm
Ashburner, J. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.07.007 · Cited by 8,122
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516 · cited 2×
“…et al., 2009), extend across several cognitive domains (Georgiades et al., 2017), persist through periods of remission of other symptoms, such as positive psychotic symptoms (Hughes et al., 2003), and are among the best predictors of functional outcome (Chang et al., 2016; Green, 1996).”
BackgroundMisunderstanding analysis of covariance.
Miller, G. A., & Chapman, J. P. (2001) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.110.1.40 · Cited by 2,136
Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
Cools, R., & D'Esposito, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.028 · Cited by 1,673
Dissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527 · cited 2×
“This task has been validated in lesion studies (Dias et al., 1996) and neuroimaging studies (Hampshire and Owen, 2006), is sensitive to pharmacological modulation (Tait et al., 2014), and has been extensively used to examine set-shifting deficits in schizophrenia (Waltz, 2017).”
BackgroundNeurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130 · cited 4×
“Developing treatments for cognitive deficits in schizophrenia is an important objective because they are severe (Mesholam-Gately et al., 2009), extend across several cognitive domains (Georgiades et al.”
BackgroundResultInfluentialMonchi, O., Petrides, M., Petre, V., Worsley, K., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07733.2001 · Cited by 961 · cited 2×
“…cortex (DLPFC) is activated in general searching (Hampshire and Owen, 2006), the ventrolateral prefrontal cortex (VLPFC; Konishi et al., 2002; Monchi et al., 2001; Rogers et al., 2000) and posterior parietal cortex (PPC; Asari et al., 2005) in ED shifting, whilst the orbitofrontal cortex…”
BackgroundDorsolateral prefrontal contributions to human working memory
Barbey, A. K., Koenigs, M., & Grafman, J. (2013) · Cortex · doi:10.1016/j.cortex.2012.05.022 · Cited by 940 · cited 2×
“Additionally, the patients show significantly reduced activity in the left DLPFC compared to the healthy comparison group, a region which may help manage the working memory component of learning and switching associations (Barbey et al., 2013).”
BackgroundResultCognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835
Research works printed but not linked: 3
- Brett M, 2002, Neuroimage, 13, 210
- Elvevag B, 2012, Crit Rev Neurobiol, 14, 1
- Roberts AC, 1988, Q J Exp Psychol B, 40, 321
Cited by
Barnett, M. M., Reay, W. R., Geaghan, M. P., Kiltschewskij, D. J., Green, M. J., Weidenhofer, J., Glatt, S. J., & Cairns, M. J. (2023) · Science Advances · doi:10.1126/sciadv.adi4386 · Cited by 55
“…a recent trial of the phosphodiesterase (PDE) inhibitor roflumilast (selective PDE4 inhibitor) demonstrated reduced errors in a cognitive flexibility task among SZ patients taking 100-μg dose for 8 days compared to both SZ patients taking placebo and patients taking a higher dose (250 μg) ( 66 ).”
Phosphodiesterase inhibitors in psychiatric disorders
Sadeghi, M. A., Nassireslami, E., Zoshk, M. Y., Hosseini, Y., Abbasian, K., & Chamanara, M. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06361-3 · Cited by 40
Veselinović, T., & Neuner, I. (2022) · CNS Drugs · doi:10.1007/s40263-022-00935-z · Cited by 32
Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia
Suárez-Santiago, J. E., Roldán, G., & Picazo, O. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000689 · Cited by 21
“For some years now, there have been different reports in the literature showing that, in patients with SCZ, there is a significant deterioration of this cognitive ability (Oades et al., 1997; Turner et al., 2004; Livingston et al., 2021).”
Roflumilast and cognition enhancement: A translational perspective
Prickaerts, J., Kerckhoffs, J., Possemis, N., van Overveld, W., Verbeek, F., Grooters, T., Sambeth, A., & Blokland, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117707 · Cited by 21
Metadata
- Authors
- Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A.
- Affiliations
- King's College London (GB)
- University of Cambridge (GB)
- Barnet Enfield and Haringey Mental Health Trust (GB)
- Department of Psychosis Studies, King’s College London, London, UK
- Corresponding author
- Mehta, Mitul A
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-04-28
- Volume
- 35
- Issue
- 9
- Pages
- 1099-1110
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC8435828
- OpenAlex
- W3157931311
- Cited by
- 17
- References
- 69
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Takeda Pharmaceutical Company (ROF-SCHZ_106)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- roflumilast, phosphodiesterase-4 inhibitors, schizophrenia, cognitive flexibility, set-shifting, reversal learning, solution search, ventrolateral prefrontal cortex, dorsolateral prefrontal cortex, posterior parietal cortex, orbitofrontal cortex, functional brain activity, cognitive enhancement
- MeSH terms
- Dorsolateral Prefrontal Cortex, Adult, Aged, Aminopyridines, Benzamides, Cyclopropanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Schizophrenia, Prefrontal Cortex, Cross-Over Studies, Phosphodiesterase 4 Inhibitors, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. https://app.cochat.ai/papers/10.1177/02698811211000778
- The paper
- Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021). Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211000778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.